652153-62-3

Usage

Uses

Used in Organic Chemistry:
TBOC is used as a protecting group for amines to facilitate selective manipulation of amine groups in complex organic molecules. This allows synthetic chemists to develop pharmaceuticals and other organic compounds with greater precision and control.
Used in Pharmaceutical Development:
In the pharmaceutical industry, TBOC is used as a protecting group for amines to enable the synthesis of complex drug molecules. Its ability to be easily removed under mild acidic conditions ensures that the amine group is preserved and available for further reactions, contributing to the development of effective and targeted medications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 22013-33-8 6-amino-3,4-benzodioxane 

Relevant academic research and scientific papers

Ligand-Promoted Meta-C-H Arylation of Anilines, Phenols, and Heterocycles

Here we report the development of a versatile 3-acetylamino-2-hydroxypyridine class of ligands that promote meta-C-H arylation of anilines, heterocyclic aromatic amines, phenols, and 2-benzyl heterocycles using norbornene as a transient mediator. More than 120 examples are presented, demonstrating this ligand scaffold enables a wide substrate and coupling partner scope. Meta-C-H arylation with heterocyclic aryl iodides as coupling partners is also realized for the first time using this ligand. The utility for this transformation for drug discovery is showcased by allowing the meta-C-H arylation of a lenalidomide derivative. The first steps toward a silver-free protocol for this reaction are also demonstrated.

Amination of aryl iodides using a fluorous-tagged ammonia equivalent

A fluorous-tagged ammonia equivalent for the Cu-catalyzed amination of aryl iodides is described in which N-Boc-protected anilines are produced in high overall yield and purity. All purification steps are performed using Fluorous SolidPhase Extraction (F-SPE) greatly simplifying and speeding up the isolation of the desired products.

Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors

On the basis of previous studies, we identified pyrazine-pyridine A as a potent vascular endothelial growth factor inhibitor and pyrimidine-pyridine B as a moderately potent cyclin dependent kinase (CDK) inhibitor. A proposed combination of CGP-60474 and

SUBSTITUTED TRIAZINE KINASE INHIBITORS

The present invention provides substituted 1,3,5-triazine compounds as kinase inhibitors and a method for treating or ameliorating a kinase mediated disorder.